Pagadin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pagadin

Property Description
Active ingredient Pregabalin
Form Oral capsule, Oral solution, Extended-release tablet
Pharmacological class Gabapentinoid, Anticonvulsant, Miscellaneous Analgesic
General use Managing chronic pain and seizure disorders
Origin Synthetic organic compound

Pagadin is a prescription-only, synthetic medicinal product that works within the central nervous system to calm overactive nerve signals. Its primary use relates to conditions involving nerve hyperactivity, classifying it as both an anticonvulsant and a miscellaneous analgesic.

1. Defining Pagadin: A Gabapentinoid and Anticonvulsant

Pagadin is a medication whose active ingredient is Pregabalin, a substance structurally related to gamma-aminobutyric acid (GABA). The drug is categorized within the gabapentinoid pharmacological class, which targets nerve activity in the brain and spinal cord to reduce excitability. Pregabalin modulates nerve signaling pathways to treat conditions like neuropathic pain. Clinically recognized for its role in stabilizing nerve function, this medicine helps soothe nerve-related discomfort by gently stabilizing nerve transmissions. As a structural derivative, Pregabalin is a synthetic organic compound, and it does not occur naturally.

2. Chemical Origin and Available Forms of Pagadin

Pregabalin is defined by its precise chemical structure, (S)-3-(aminomethyl)-5-methylhexanoic acid, a compound with the formula C8H17NO2. This synthetic origin ensures consistency and purity in the final pharmaceutical preparation. The various pharmaceutical preparations are designed to meet different patient needs, consisting of the active compound and necessary excipients. The conventional formulations, such as the oral capsule, are immediate-release, while specialized dosage forms like the extended-release tablets are available to provide a prolonged and consistent therapeutic effect over time. This variety in dosage form is a key distinguishing feature, accommodating the different therapeutic profiles needed for managing chronic conditions.

3. General Purpose and Mechanism of Action

The general purpose of Pagadin is rooted in its role as an alpha2delta ligand, which describes its core interaction with nerve cells. This mechanism involves highly selective binding to the alpha2delta subunit of voltage-gated calcium channels (VGCCs). By achieving this targeted effect, Pregabalin modulates the release of excitatory neurotransmitters such as Glutamate. This stabilizing action provides the necessary analgesic activity and anticonvulsant activity required to quiet symptoms associated with chronic neuropathic pain and specific types of seizure disorders driven by hyperactive nerves in the Central Nervous System (CNS).

Regulatory References

  1. Pregabalin - NLM
  2. Pregabalin Drug Information

What side effects are possible with Pagadin?

Possible Side Effects and Safety Information

Adverse reactions associated with Pagadin are formally classified based on frequency as reported in clinical studies, with the profile primarily involving the Central Nervous System (CNS).

Frequency Classification Examples of Adverse Reactions (System-Organ Classes)
Very Common (ge 1/10) Dizziness, Somnolence (Nervous System Disorders)
Common (ge 1/100 to < 1/10) Blurred vision, Weight gain, Peripheral edema, Euphoric mood, Dry mouth (Eye, Metabolic, Psychiatric, and Gastrointestinal Disorders)

Serious Adverse Reactions and Safety Constraints

The regulatory label documents severe reactions and population-specific considerations. Serious adverse reactions include Angioedema (swelling of the face, lips, or throat), Respiratory Depression (especially when co-administered with other CNS depressants), and an increased risk of Suicidal Ideation and Behavior [FDA, EMA]. The drug is designated as a controlled substance due to its potential for abuse and dependence.

Population-Specific and Time-Related Safety

Dizziness and Somnolence are noted to be most frequent at the beginning of treatment [EMA]. The label indicates that patients with renal impairment require a dose adjustment due to the way the medicine is eliminated from the body. Older adults may experience a higher risk of accidental injury (falls) related to dizziness and somnolence [FDA]. Withdrawal symptoms, such as headache, nausea, and insomnia, may occur upon abrupt discontinuation.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory documents define the Pagadin overdose profile based on documented Central Nervous System (CNS) effects. Manifestations commonly reported in official sources include somnolence, a confusional state, agitation, and reduced consciousness. More severe presentations documented include seizures and deep CNS depression leading to coma.

The most serious outcomes are severe respiratory depression and, in rare instances, death; these life-threatening events are reported primarily when Pagadin is co-ingested with other CNS depressants, such as alcohol or opioids. Official guidance requires immediate action: Seek urgent medical attention or emergency services if any severe symptoms occur, specifically trouble breathing (slow or shallow), extreme sleepiness, or the inability to wake up or respond.

The official regulatory profile confirms that no specific antidote is known for Pagadin overdose. Management is limited to symptomatic and supportive treatment, including the maintenance of the airway and continuous monitoring of vital signs. Procedural interventions described include the use of emesis or gastric lavage for unabsorbed drug, and hemodialysis is cited as an effective method for drug removal, particularly relevant for patients with decreased kidney function.

Therapeutic Uses of Pagadin

What Pagadin Treats: Main Uses and Benefits

The medication is commonly used across therapeutic domains involving symptoms related to heightened physiological activity. It is considered relevant in conditions where symptoms may interfere with functional stability, assisting with the overall symptom burden. This includes several major conditions.

Pagadin may be applied in addressing conditions presenting with systemic or localized discomfort, such as diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain, Fibromyalgia, and Generalized Anxiety Disorder (GAD). It is also commonly used as supportive therapy alongside other medicines for individuals who experience partial-onset seizures. The medication may assist with easing symptom clusters characterized by abnormal, distressing sensations, and supports patients during episodes of heightened discomfort.

Quick Fact: Relief for Chronic Nerve Pain

Pagadin may be part of symptomatic management for sharp, burning, or shooting nerve pain, supporting general well-being during symptomatic phases. It provides supportive relief when symptoms create noticeable physiological strain.

Regulatory References

  1. European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Official Eligibility and Population Restrictions

Regulatory documents define eligibility for Pagadin (Pregabalin) based on specific patient populations and health statuses. Use is contraindicated in any patient with a known hypersensitivity to the active substance or its excipients.

Population Official Regulatory Status
Adults (17 years and older) Approved for all labeled indications.
Pediatrics (1 month +) Established for adjunctive therapy of partial-onset seizures only.
Pediatrics (< 12 years) Safety and efficacy not established for non-seizure indications.
Older Adults (≥ 65 years) May require dose adjustment due to likely reduced renal function.

Condition-Specific Eligibility: Pagadin is primarily eliminated by the kidneys. Therefore, individuals with renal impairment (reduced kidney function) must have their dosage adjusted to prevent systemic accumulation, a requirement explicitly detailed in the labeling. Conversely, no dose adjustment is required for patients with hepatic impairment. Patients with a history of angioedema or substance abuse are subject to cautionary use and close regulatory monitoring.

Reproductive Status: Use during pregnancy is generally advised against due to the potential risk of fetal harm; women of childbearing potential are advised to use effective contraception. Breastfeeding is not recommended as the substance is present in human breast milk.

What should I know about interactions with other medicines?

Pagadin Interactions with other Medicines and Products

The interaction profile of Pagadin (Pregabalin) is primarily defined by pharmacodynamic effects, as the medication is minimally metabolized and does not significantly inhibit or induce major CYP450 enzymes according to regulatory documentation. The majority of clinically significant interactions involve additive effects with other substances.

Documented Pharmacodynamic Interactions

Substance Category Documented Interaction Pattern
Central Nervous System (CNS) Depressants Co-administration with substances like opioid analgesics, benzodiazepines, and alcohol (ethanol) is associated with an increased risk of severe CNS depression, including enhanced sedation and dizziness. This can lead to an elevated risk of respiratory depression.
Hypoglycaemic Medicines Co-use with thiazolidinediones (e.g., Pioglitazone) is documented to increase the risk of weight gain and peripheral edema (fluid retention).
Medicines Causing Constipation Co-administration with opioid analgesics is associated with an increased risk of reduced lower gastrointestinal tract function, such as severe constipation.

Formulations and Population Cautions

  • Alcohol: Official regulatory information discourages the use of alcohol due to the potential for potentiated CNS depressant effects.
  • Extended-Release Tablets: The labeling for this specific formulation requires administration after an evening meal.
  • Population Risk: Regulatory documents highlight an increased risk of severe respiratory depression with CNS depressants in the elderly and in patients with pre-existing compromised respiratory function.

Mechanism of Action

How Pagadin Works

alpha2delta Modulation of Presynaptic Channels

Pagadin’s mechanism begins with its highly selective binding to the alpha2delta subunit of Voltage-Gated Calcium Channels (VGCCs) on nerve endings in the central nervous system. This molecular interaction does not block the channel, but functionally modulates it, resulting in a reduction in the density of active channels available for use. This functional reduction diminishes the necessary influx of calcium ions into the presynaptic terminal, initiating the subsequent steps of the pathway.

Attenuation of Excitatory Neurotransmitter Release

The primary physiological consequence of reduced calcium influx is a direct, concentration-dependent decrease in the release of excitatory neurotransmitters, particularly Glutamate and excitatory peptidergic mediators such as Substance P. By targeting the presynaptic machinery that releases these signals, the molecule alters signaling dynamics in the neural pathways contributing to heightened neuronal signaling.

Targeted Modulation of Hyperexcited Networks

This cascade culminates in the functional attenuation of signal propagation in hyperexcited nerve networks. Pagadin acts within domains that regulate overactive processes, specifically reducing the intensity of sustained neuronal communication throughout the affected central pathways. This mechanism establishes a modulated state within targeted systems, primarily affecting pathologically overactive transmission rather than suppressing normal physiological signaling.

Dosage and Administration Information

How to Use Pagadin: Official Administration Guidelines

This section outlines the instructions for administering Pagadin (repaglinide), focusing on proper usage and dosing parameters.


Official Dosing and Administration

Pagadin is an oral medication, available in tablet strengths of 0.5 mg, 1 mg, and 2 mg. Its use is strictly meal-dependent.

Guideline Official Instruction
Route Oral (taken by mouth).
Timing Must be taken within 30 minutes before a main meal (preprandially).
Standard Dosing The typical starting dose is 0.5 mg before each main meal. The maximum single dose is 4 mg.
Maximum Daily Limit The total daily dose must not exceed 16 mg.

Flexible Regimen and Procedural Rules

The frequency of Pagadin administration is flexible, reflecting a patient's eating habits, and may be taken 2, 3, or 4 times daily.

  • Missed Meal Rule: If a meal is skipped, the scheduled dose of Pagadin must also be skipped. Do not take the dose if no food is consumed.
  • Added Meal Rule: If an extra meal is eaten, a dose may be added for that specific meal.
  • Dose Adjustment: Dosage changes should be made gradually, with at least one week allowed to assess the response before any further adjustment is made.

Population Adjustments

Patients with severe kidney impairment should initiate treatment with a lower dose of 0.5 mg before each main meal, with careful and slower titration. Conservative initial and maintenance dosing is also required for patients with liver impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Pagadin

The research base for Pagadin (Pregabalin) centers on clinical evaluations that examine the medicine’s use in conditions related to nerve signaling. Studies primarily include randomized, controlled trials (RCTs), which compare outcomes in people receiving Pagadin against a control group, and systematic reviews, which compile and analyze findings from multiple trials. The purpose of this research overview is to describe how the medication was studied for various types of nerve pain and seizure disorders, and to outline the patterns observed in the studies.


Research Evidence for Chronic Nerve Pain

Evidence for Painful Diabetic Peripheral Neuropathy (DPN)

Research for DPN primarily uses short-term Randomized Controlled Trials (RCTs), which explored how symptoms changed over time in adults diagnosed with painful DPN. The specific outcomes research monitored included measurements of pain intensity using standardized scales, scores related to sleep interference, and the percentage of participants reaching defined pain relief thresholds.

Findings from the short-term treatment periods (generally lasting up to 14 weeks) described patterns in the data collected. Controlled data providing insight into outcomes beyond the short-term are limited. The available long-term effects are not fully established and mostly rely on follow-up observations from open-label extension studies, which do not use a control group for comparison.

Evidence for Postherpetic Neuralgia (PHN)

Research for Postherpetic Neuralgia (PHN) was also evaluated using controlled trials. The evidence primarily consists of short-term RCTs that examined changes in pain intensity and health-related quality of life (HRQoL). The research describes the short-term changes measured in pain intensity and sleep interference scores, but there is limited information for long-term outcomes regarding the maintenance of observed effects.

Evidence for Neuropathic Pain Related to Spinal Cord Injury (SCI)

Research for neuropathic pain associated with a Spinal Cord Injury (SCI) was studied for adults with chronic nerve pain below the site of injury. While some controlled trials describe patterns in pain scores, the overall body of evidence for SCI pain is limited, and the evidence quality varies across studies (coarsely graded as low). Data for certain groups remain insufficient, and the findings were mixed regarding the consistency of outcomes.


Research Evidence for Fibromyalgia and Generalized Anxiety Disorder (GAD)

Evidence for Fibromyalgia

Fibromyalgia (FM) research involved Intermediate-term Randomized Controlled Trials, examining patient-reported outcomes including weekly pain scores, sleep quality, and daily functioning or activity level. The studies report measurements taken over periods lasting up to six months. However, the observed outcomes rely heavily on subjective, patient-reported outcomes. Furthermore, the results apply only to the populations studied.

Evidence for Generalized Anxiety Disorder (GAD)

For Generalized Anxiety Disorder (GAD), the evidence base includes short-term Randomized Controlled Trials and subsequent maintenance studies. The studies monitored changes in anxiety severity scores (e.g., HAM-A). Comparative evidence is lacking against the full spectrum of other established GAD treatments, and the follow-up durations were limited for many of the pivotal controlled trials.


Research Evidence as Adjunctive Therapy for Partial-Onset Seizures

Pagadin was evaluated in adults and adolescents (age 12 and older) for partial-onset seizures not fully controlled by existing medication. The evidence is established for use as an adjunctive (add-on) therapy. Study results reflect research conducted in participants whose seizures were refractory to previous anti-epileptic drug therapy. However, there is limited information regarding outcomes if Pagadin was used alone (monotherapy).


Duration of Study and Long-Term Follow-up

The duration of most pivotal controlled trials assessing short-term or episodic symptom patterns ranges from 4 to 26 weeks. This means that controlled, comparative evidence primarily describes the short-term changes in outcomes. While long-term effects are not fully established, open-label extension studies have monitored outcomes for periods up to a year or longer.


Research Gaps and Areas of Uncertainty

The main evidence highlights what is known — and what is still uncertain. Follow-up durations were limited in most controlled studies, and there is a notable reliance on patient-reported outcomes for many endpoints. Evidence quality varies across studies, and comparative evidence is lacking against all similar therapies. This means that studies help show what has been observed so far, and the research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety
  2. Pregabalin as adjunctive therapy for partial seizures (Combined results of three studies)
  3. Does pregabalin offer potential as a first-line therapy for generalized anxiety disorder? A meta-analysis of efficacy, safety, and cost-effectiveness

Frequently Asked Questions (FAQ)

Common questions about Pagadin (FAQ)


Q: Is Pagadin a type of painkiller or something else entirely?

A: According to official product information, Pagadin (Pregabalin) is classified as both an anticonvulsant and a miscellaneous analgesic, which means it has pain-relieving properties. It works by regulating overactive nerve signals in the central nervous system to address conditions involving nerve hyperactivity.

Q: Does Pagadin make you feel sleepy or tired?

A: Yes, regulatory documents indicate that somnolence (sleepiness or drowsiness) is a very common adverse reaction. This frequency classification means it is one of the most frequently reported side effects in clinical trials (occurring in 1 out of 10 people or more).

Q: Can Pagadin affect my ability to drive or operate machinery?

A: Due to the potential for dizziness and somnolence, official warnings indicate that the medication may impair the ability to perform tasks requiring focused attention, such as driving or operating complex machinery. Patients should proceed with caution until they understand how the medication affects them.

Q: Are there any long-term side effects from taking Pagadin?

A: Most key clinical trials were short-term, meaning the full long-term effects of Pagadin are not fully established by comparative controlled studies. While some effects like weight gain may increase over time, safety information for long-term use is gathered from observation studies.

Q: What happens if I miss a dose of Pagadin?

A: The administration rules for Pagadin are flexible. If a meal is skipped, the dose of Pagadin scheduled for that meal must also be skipped. If a dose is missed but the meal is eaten, official product instructions state that the missed dose should be skipped, and the next scheduled dose should be taken as planned.

Q: Do I need to take Pagadin with food?

A: The immediate-release forms of Pagadin may be taken with or without food. However, official instructions often specify that the dose should be taken within 30 minutes before a main meal. Patients should follow the specific instructions provided in the regulatory labeling for their prescribed formulation.

Q: Can Pagadin interact with my birth control pills?

A: Pagadin is minimally metabolized by the body and has a low potential to interfere with hormonal contraceptives. However, regulatory documents note that women of childbearing potential are recommended to use effective contraception during treatment.

Q: How does Pagadin work inside the body to help with my condition?

A: Pagadin acts on nerve cells in the brain and spinal cord by selectively binding to a specific site (alpha2delta subunit). This action reduces the release of excitatory chemical signals, such as Glutamate, that contribute to overactive nerve transmission. This mechanism helps to modulate, or quiet, signal transmission in central nerve networks that may be overactive.

Q: Does Pagadin have any warnings about alcohol consumption?

A: Yes, official regulatory documents discourage the use of alcohol while taking Pagadin. Combining the two substances can significantly increase the risk of side effects such as dizziness and sedation, potentially leading to enhanced central nervous system depression.

Q: Can Pagadin interact with herbal supplements like St. John's Wort?

A: The drug label does not specifically list St. John's Wort or most other herbal supplements as known interactions. Since Pagadin acts primarily via the central nervous system, care must be taken with any products that also cause drowsiness or sedation. Patients should discuss all concurrent use of supplements with a healthcare provider to ensure complete assessment of potential interactions.

Q: Does Pagadin cause any weight gain or loss?

A: The drug label lists weight gain as a common side effect reported during clinical trials, meaning it was observed in a moderate number of patients. Weight loss is not generally listed as a frequent side effect in the official safety profile.

Q: How is Pagadin eliminated or flushed out of the body?

A: Pagadin is eliminated almost entirely by the kidneys and is excreted as the unchanged drug. This means it is not significantly broken down by the liver. Because of this, patients with reduced kidney function often require a dosage adjustment.

Q: Can taking Pagadin affect my mood or anxiety levels?

A: Studies report that euphoric mood is a common adverse reaction associated with Pagadin. Additionally, the drug label contains an official warning regarding an increased risk of suicidal ideation and behavior. This potential risk is highlighted in the label, which emphasizes the need for careful patient observation.

Q: Is there a generic version of Pagadin available?

A: Yes, the active ingredient in Pagadin, which is Pregabalin, is widely available as a generic drug. Generic forms are produced by multiple manufacturers and are available in various formulations, subject to local regulatory approvals.

Q: How long does the effect of one dose of Pagadin last?

A: The elimination half-life of Pagadin is approximately 6.3 hours, which is the time it takes for half of the drug to be cleared from the system. This half-life supports the typical twice or thrice daily dosing schedule used for immediate-release formulations to maintain stable blood levels.

Q: Are there specific foods I should avoid while on Pagadin?

A: The official regulatory documents do not list any specific foods that must be avoided while taking Pagadin. The medication can be taken regardless of food composition, as it does not have known food-related restrictions.

Q: Can Pagadin interact with common cold or flu medicines?

A: Caution is necessary because Pagadin interacts with other Central Nervous System (CNS) depressants. Some common cold and flu medicines contain ingredients, such as certain opioid cough suppressants or antihistamines, that are CNS depressants. Combining them can increase sedation, dizziness, and other CNS-related side effects.

Q: Do I need to taper off Pagadin, or can I stop taking it suddenly?

A: To minimize the risk of withdrawal symptoms such as headaches, insomnia, and nausea, official regulatory documents indicate that if discontinuing treatment, the dose is typically gradually reduced over a period of at least one week.

Q: Can I take Pagadin if I have a heart condition?

A: The drug label does not list a heart condition as a strict contraindication, but it does note that the medication can cause peripheral edema (fluid retention). Patients with pre-existing heart failure are recommended to be monitored for worsening status.

Q: Is it okay to take antacids close to when I take Pagadin?

A: The drug label does not list any direct interaction between Pagadin and common antacids. Since Pagadin is mostly excreted unchanged by the kidneys and not significantly metabolized, antacids are not expected to interfere with how the body absorbs or processes it.

Q: Are there any reported cases of dependence or addiction with Pagadin?

A: The drug label designates Pagadin as a controlled substance due to its potential for abuse and dependence. Furthermore, symptoms suggesting physical dependence have been reported when the medication is abruptly stopped.

Q: What are the most common reasons people stop taking Pagadin?

A: In clinical trials, the most frequent adverse reactions that led patients to stop taking Pagadin were related to its central nervous system effects. The most common reasons for discontinuation were dizziness and somnolence (sleepiness).

Q: What happens if I accidentally take two doses of Pagadin too close together?

A: In the event of accidental overdose or taking doses too closely, it is recommended to consult a healthcare professional. Adverse events reported in cases of overdose have included confusion, reduced consciousness, and agitation.

Q: Are there any restrictions on physical activity while taking Pagadin?

A: Official warnings note the risk of falls, particularly in older adults, due to potential dizziness and somnolence. No blanket restrictions on physical activity are listed, but this indicates that activities requiring good balance or high alertness may be affected.

Q: What is the shelf life of Pagadin tablets?

A: Official instructions require that the medication be stored in its original, tightly closed container at room temperature, typically below 25 C. The official regulatory requirements state that the exact shelf life and expiry date are located on the manufacturer's original packaging.

Q: Can Pagadin cause changes in vision?

A: Yes, blurred vision is listed as a common side effect in the official safety information. Official safety information notes that any changes in vision should be discussed with a healthcare provider.

Q: Do I need regular blood tests while on Pagadin?

A: The regulatory label does not mandate routine blood tests for all patients. However, monitoring may be advised for certain conditions, such as for patients with renal impairment or if signs of rare muscle-related side effects arise.

Q: Why do some people experience better results with Pagadin than others?

A: Clinical trial results show a variable response across patients. Regulatory documents explicitly state that the research findings apply only to the studied populations and do not determine whether an individual will respond similarly. Patient response is influenced by many individual factors.

Q: Can Pagadin be taken with other prescription pain medications?

A: Caution is advised when Pagadin is taken with opioid analgesics because this combination significantly increases the risk of severe CNS depression and respiratory problems. For all other prescription pain medications, a healthcare professional should be consulted to review potential additive effects or interactions.

Q: What is the difference between an oral capsule and an extended-release tablet of Pagadin?

A: The standard oral capsule is an immediate-release formulation, which provides a rapid release of the drug. The extended-release (ER) tablet is a specialized dosage form that provides a prolonged and consistent therapeutic effect over a much longer period, allowing it to often be dosed once daily.

How should Pagadin be stored and disposed of?

The storage and disposal of Pagadin (Pregabalin) must follow the instructions provided in the official regulatory labeling.

Required Storage Conditions

Pagadin must be stored at room temperature, which typically requires the area to be kept below 25°C. The medicine must be protected from excess heat and moisture and should not be stored in humid locations like a bathroom. To maintain product stability, the medication must be kept in the original container and the container must remain tightly closed.

Safety and Disposal

All Pagadin medication must be stored out of the sight and reach of children in a secure location. Unused or expired medication must be disposed of through an authorized medicine take-back program or by returning it to a pharmacist. Disposal must comply with local regulations and unused product should not be thrown into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pagadin found in:

A-Z Index: